Accentia gets $4M for drug R&D

  • By Business Observer Staff
  • | 4:13 p.m. June 15, 2011
  • Tampa Bay-Lakeland
  • Share

TAMPA — Accentia Biopharmaceuticals Inc. (symbol: ABPI) received $4 million in financing for the development of Revimmune, a drug the company is creating to treat autoimmune diseases such as multiple sclerosis.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • April 8, 2026
Brandon Bahama Breeze to close after Darden backtracks on decision
  • April 8, 2026
Developing Sarasota dining club to buy neighboring property
  • April 8, 2026
Lee Health turns to robotics to help treat liver cancer
  • April 8, 2026
Tervis acquires Nashville drinkware company

Sponsored Content